Providing Quality HIV Care

Jan. 20, 2020: Protease inhibitors and heart attack risk; HIV status and pericardial adipose tissue volume; cardiovascular risk profiles on TDF vs. TAF; hemostatic profiles in older people living with HIV.

Feb. 13, 2020: PrEP's psychosocial benefits; supplementing ADAP with Obamacare plans; lack of HIV and HCV testing for people who inject drugs; frailty is more common, but not more deadly, in HIV settings.

While the vaginal ring is still currently under FDA review, the new study will show whether it is safe and acceptable for people who are pregnant.

Feb. 6, 2020: HIV medication costs outpace inflation; HIV's role in attenuating childhood vaccinations; the challenges of researching effects of medications during pregnancy; the need for localized HIV interventions in the U.S.

Jan. 30, 2020: Polypharmacy vs. drug interaction risk among people living with HIV as they age; cost-effectiveness of ibalizumab; PrEP persistence on Medicaid vs. private health coverage.

Using data from the ADVANCE trial, this researcher suggests people with HIV with low-level viremia may still get to undetectable.

Health care providers and educators need to acknowledge the impact of clinical bias and reframe sexual health education when it comes to tending to cisgender women's needs, Chase Alston writes.

Many fear the push to put more people on the new brand-name drug before Truvada goes generic this year.

Descovy’s approval for PrEP showcases real-life ramifications of leaving trans people out of research. But including trans people is about more than just saying trans people are welcome, says researcher Brian Minalga.

Jan. 23, 2020: Neurocognitive benefits of cannabis use; how unquantifiable HIV in CSF correlates to executive function; updated findings on efavirenz and microcephaly; cost-efficacy of a specialized HIV care coordination team.